IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$1.37
−15.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | (33.9K) | 29.3K | 165.8K | 63.1K | — |
| Cost of Revenue | 4.9M | 7.3M | 3.3M | 532.3K | — |
| Gross Profit | (4.9M) | (7.2M) | (3.2M) | (469.2K) | — |
| Operating Expenses | |||||
| R&D Expense | 17.2M | 25.7M | 35.4M | 41.0M | 37.5M |
| SG&A Expense | 11.6M | 17.6M | 19.3M | 16.1M | 14.3M |
| General & Admin Expense | 12.9M | 15.5M | 15.3M | 14.2M | 14.3M |
| Selling & Marketing Expense | (1.3M) | 2.0M | 4.0M | 1.9M | — |
| Other Expenses | (1.0M) | (2.3M) | (4.9M) | (13.0M) | (19.6M) |
| Total Operating Expenses | 27.8M | 41.0M | 49.8M | 44.1M | 32.2M |
| Cost and Expenses | 32.6M | 48.3M | 53.1M | 44.7M | 32.2M |
| Operating Income (EBIT) | (32.7M) | (48.3M) | (52.9M) | (44.6M) | (32.2M) |
| Non-Operating | |||||
| Interest Income | 2.6M | 1.8M | 3.2M | 3.8M | 608.7K |
| Interest Expense | 59.7K | 37.7K | 20.7K | 35.6K | 45.3K |
| Net Interest Income | 2.5M | 1.7M | 3.2M | 3.8M | 563.4K |
| Other Non-Op Income/Expense | 3.3M | 2.6M | 6.8M | 1.9M | 2.8M |
| Non-Operating Income (excl Interest) | (3.4M) | (2.7M) | (6.9M) | (2.0M) | (2.8M) |
| EBT (Pre-Tax Income) | (29.3M) | (45.6M) | (46.1M) | (42.7M) | (29.5M) |
| Income Tax Expense | — | 12.3K | 5.2K | — | — |
| Bottom Line | |||||
| Net Income | (29.3M) | (45.6M) | (46.1M) | (42.7M) | (29.5M) |
| Earnings from Cont. Ops | (29.3M) | (45.6M) | (46.1M) | (42.7M) | (29.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (29.3M) | (45.6M) | (46.1M) | (42.7M) | (29.5M) |
| Per Share | |||||
| Basic EPS | ($0.33) | ($0.66) | ($0.78) | ($0.78) | ($0.61) |
| Diluted EPS | ($0.33) | ($0.66) | ($0.78) | ($0.78) | ($0.61) |
| Revenue Per Share | ($0.00) | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 147.4M | 67.3M | 58.9M | 54.9M | 44.2M |
| Diluted Shares Outstanding | 147.4M | 67.3M | 58.9M | 54.9M | 44.2M |
| Profitability Metrics | |||||
| EBITDA | (28.9M) | (45.2M) | (45.6M) | (42.1M) | (28.8M) |
| D&A | 355.8K | 419.5K | 485.1K | 567.8K | 596.6K |
| EBIT | (29.3M) | (45.6M) | (46.0M) | (42.6M) | (29.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026